Hypoxia-Inducible Factor (HIF) as a Pharmacological Target for Prevention and Treatment of Infectious Diseases

被引:46
作者
Bhandari T. [1 ]
Nizet V. [1 ,2 ,3 ]
机构
[1] Center for Immunity, Infection and Inflammation, Department of Pediatrics and Biomedical Sciences Graduate Program, University of California, San Diego, La Jolla
[2] Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla
[3] Center for Immunity, Infection and Inflammation, Medical Sciences Research 4113, University of California, San Diego, 9500 Gilman Drive, MC 0760, La Jolla, 92093-0760, CA
基金
美国国家卫生研究院;
关键词
Bacteria; Dendritic cells; Hypoxia-inducible factor; Innate immunity; Macrophages; Neutrophils; T cells; Virus;
D O I
10.1007/s40121-014-0030-1
中图分类号
学科分类号
摘要
In the present era of ever-increasing antibiotic resistance and increasingly complex and immunosuppressed patient populations, physicians and scientists are seeking novel approaches to battle difficult infectious disease conditions. Development of a serious infection implies a failure of innate immune capabilities in the patient, and one may consider whether pharmacological strategies exist to correct and enhance innate immune cell function. Hypoxia-inducible factor-1 (HIF-1), the central regulator of the cellular response to hypoxic stress, has recently been recognized to control the activation state and key microbicidal functions of immune cells. HIF-1 boosting drugs are in clinical development for anemia and other indications, and could be repositioned as infectious disease therapeutics. With equal attention to opportunities and complexities, we review our current understanding of HIF-1 regulation of microbial host–pathogen interactions with an eye toward future drug development. © 2014, The Author(s).
引用
收藏
页码:159 / 174
页数:15
相关论文
共 119 条
[1]  
Wang G.L., Jiang B.H., Rue E.A., Semenza G.L., Hypoxia-inducible factor 1 is a basic-helix–loop–helix-PAS heterodimer regulated by cellular O2 tension, Proc Natl Acad Sci USA, 92, pp. 5510-5514, (1995)
[2]  
Semenza G.L., Wang G.L., A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation, Mol Cell Biol, 12, pp. 5447-5454, (1992)
[3]  
Nizet V., Johnson R.S., Interdependence of hypoxic and innate immune responses, Nat Rev Immunol, 9, pp. 609-617, (2009)
[4]  
Heikkila M., Pasanen A., Kivirikko K.I., Myllyharju J., Roles of the human hypoxia-inducible factor (HIF)-3α variants in the hypoxia response, Cell Mol Life Sci, 68, pp. 3885-3901, (2011)
[5]  
Tian H., McKnight S.L., Russell D.W., Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells, Genes Dev, 11, pp. 72-82, (1997)
[6]  
Ema M., Taya S., Yokotani N., Sogawa K., Matsuda Y., Fujii-Kuriyama Y., A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development, Proc Natl Acad Sci USA, 94, pp. 4273-4278, (1997)
[7]  
Talks K.L., Turley H., Gatter K.C., Maxwell P.H., Pugh C.W., Ratcliffe P.J., Et al., The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages, Am J Pathol, 157, pp. 411-421, (2000)
[8]  
Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., Et al., HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing, Science, 292, pp. 464-468, (2001)
[9]  
Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., Et al., Targeting of HIF-α to the von Hippel–Lindau ubiquitylation complex by O<sub>2</sub>-regulated prolyl hydroxylation, Science, 292, pp. 468-472, (2001)
[10]  
Ebert B.L., Bunn H.F., Regulation of transcription by hypoxia requires a multiprotein complex that includes hypoxia-inducible factor 1, an adjacent transcription factor, and p300/CREB binding protein, Mol Cell Biol, 18, pp. 4089-4096, (1998)